AT-007 receives FDA Pediatric Rare Disease Designation
AT-007 receives FDA Pediatric Rare Disease Designation for Galactosemia
emarr
September 22, 2020
AT-007 receives FDA Pediatric Rare Disease Designation for Galactosemia
Positive Phase 1/2 topline data from pivotal ACTION-Galactosemia study
Phase 3 registrational trial (ARISE-HF) of AT-001 in Diabetic Cardiomyopathy initiated
Company founding
Successful IPO on NASDAQ
AT-007 receives FDA Orphan Designation for Galactosemia
Positive topline data from AT-001 Phase 1/2 trial for Diabetic Cardiomyopathy
ACTION-Galactosemia study in adults initiated
©2020 Applied Therapeutics All Rights Reserved